(2) When head and neck and esophageal squamous cell carcinomas become resistant to PI3Kα inhibition, AXL dimerizes with EGFR and activates EGFR/PKC/mTOR pathway46. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.